Abiopharma

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

Covalon Reports Highest Revenue Quarter of Fiscal Year 2025, Delivers Third Consecutive Year of Revenue Growth

Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon

Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council

Redecan Cannabis Brand Elevates the Diamond Vape Category with the Launch of Amped Live Resin Liquid Diamond Vapes

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Bristol Myers Squibb - U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibbs Application forOpdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma